PACB - 2019 Q1

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission File Number 001-34899

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 



 

Delaware

16-1590339

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)



 

1305 O’Brien Drive

Menlo Park, CA

94025

(Address of principal executive offices)

(Zip Code)

(650) 521-8000

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

 

 



 

 

 

Large accelerated filer

Accelerated filer   



 

 

 

Non-accelerated filer

 

Smaller reporting company

Emerging growth company       

 

 



Securities registered pursuant to section 12(b) of the Act

 

 



 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PACB

The NASDAQ Stock Market LLC


 

Table of Contents

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of shares outstanding of the issuer’s common stock as of April 30, 2019:  152,674,751   

2

 


 

Table of Contents

 

TABLE OF CONTENTS







 



PAGE No.



 

PART I - FINANCIAL INFORMATION

 



 

Item 1. Financial Statements (unaudited):

 



 

Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 



 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2019 and 2018 



 



 

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2019 and 2018  



 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and 2018 



 

Notes to Condensed Consolidated Financial Statements 



 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 

24 



 

Item 3. Quantitative and Qualitative Disclosures About Market Risk 

30 



 

Item 4. Controls and Procedures 

30 



 

PART II. OTHER INFORMATION

 



 

Item 1. Legal Proceedings 

31 



 

Item 1A. Risk Factors 

31 



 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 

55 



 

Item 3. Default Upon Senior Securities 

55 



 

Item 4. Mine Safety Disclosures 

55 



 

Item 5. Other Information 

55 



 

Item 6. Exhibits 

55 







3

 


 

Table of Contents

 

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Balance Sheets

(Unaudited)







 

 

 

 

 



 

 

 

 

 



March 31,

 

December 31,

(in thousands, except per share amounts)

2019

 

2018

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

38,205 

 

$

18,844 

Investments

 

44,667 

 

 

83,510 

Accounts receivable

 

7,279 

 

 

8,595 

Inventory

 

19,650 

 

 

17,878 

Prepaid expenses and other current assets

 

2,787 

 

 

2,832 

Total current assets

 

112,588 

 

 

131,659 

Property and equipment, net

 

33,613 

 

 

34,073 

Operating lease right-of-use assets, net

 

34,811 

 

 

 —

Long-term restricted cash

 

4,500 

 

 

4,500 

Other long-term assets

 

65 

 

 

43 

Total assets

$

185,577 

 

$

170,275 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

$

8,740 

 

$

6,736 

Accrued expenses

 

11,158 

 

 

12,823 

Deferred service revenue, current

 

6,428 

 

 

6,537 

Operating lease liabilities, current

 

3,521 

 

 

 —

Notes payable, current

 

14,938 

 

 

 —

Other liabilities, current

 

312 

 

 

788 

Total current liabilities

 

45,097 

 

 

26,884 

Deferred service revenue, non-current

 

769 

 

 

890 

Operating lease liabilities, non-current

 

44,861 

 

 

 —

Deferred rent, non-current

 

 —

 

 

13,765 

Notes payable, non-current

 

 —

 

 

14,659 

Financing derivative

 

 —

 

 

16 

Total liabilities

 

90,727 

 

 

56,214 



 

 

 

 

 

Commitments and contingencies

 

 

 

 

 



 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred stock, $0.001 par value:

 

 

 

 

 

Authorized 50,000 shares; No shares issued or outstanding

 

 —

 

 

 —

Common stock, $0.001 par value:

 

 

 

 

 

Authorized 1,000,000 shares; issued and outstanding 152,672 and 150,244 shares at March 31, 2019 and December 31, 2018, respectively

 

153 

 

 

150 

Additional paid-in capital

 

1,107,121 

 

 

1,096,053 

Accumulated other comprehensive income (loss)

 

 

 

(36)

Accumulated deficit

 

(1,012,430)

 

 

(982,106)

Total stockholders’ equity

 

94,850 

 

 

114,061 

Total liabilities and stockholders’ equity

$

185,577 

 

$

170,275 



 

 

 

 

 

See accompanying notes to the condensed consolidated financial statements.

4

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)











 

 

 

 

 

 



 

 

 

 

 

 



Three Months Ended March 31,

 

(in thousands, except per share amounts)

2019

 

2018

 

Revenue:

 

 

 

 

 

 

Product revenue

$

13,457 

 

$

16,282 

 

Service and other revenue

 

2,968 

 

 

3,080 

 

Total revenue

 

16,425 

 

 

19,362 

 

Cost of revenue:

 

 

 

 

 

 

Cost of product revenue

 

8,618 

 

 

9,019 

 

Cost of service and other revenue

 

2,690 

 

 

3,047 

 

Total cost of revenue

 

11,308 

 

 

12,066 

 

Gross profit

 

5,117 

 

 

7,296 

 

Operating expense:

 

 

 

 

 

 

Research and development

 

15,485 

 

 

16,311 

 

Sales, general and administrative

 

19,766 

 

 

14,934 

 

Total operating expense

 

35,251 

 

 

31,245 

 

Operating loss

 

(30,134)

 

 

(23,949)

 

Interest expense

 

(625)

 

 

(581)

 

Other income, net

 

435 

 

 

351 

 

Net loss

 

(30,324)

 

 

(24,179)

 

Other comprehensive income (loss):

 

 

 

 

 

 

Unrealized income (loss) on investments

 

42 

 

 

(6)

 

Comprehensive loss

$

(30,282)

 

$

(24,185)

 



 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

Basic and diluted net loss per share

$

(0.20)

 

$

(0.20)

 

Shares used in computing basic and diluted net loss per share

 

151,274 

 

 

123,768 

 



 

 

 

 

 

 



See accompanying notes to the condensed consolidated financial statements.

5

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)







 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 



 

 

 

 

 

 

Additional

 

Other

 

 

 

 

Total



 

 

 

 

 

 

Paid-in

 

Comprehensive

 

Accumulated

 

Stockholders'

(in thousands)

 

Common Stock

 

Capital

 

Income (Loss)

 

Deficit

 

Equity



 

Shares

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2018

 

150,244 

 

$

150 

 

$

1,096,053 

 

$

(36)

 

$

(982,106)

 

$

114,061 

Net loss

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

(30,324)

 

 

(30,324)

Other comprehensive income

 

 —

 

 

 —

 

 

 —

 

 

42 

 

 

 —

 

 

42 

Issuance of common stock in conjunction with equity plans

 

2,428 

 

 

 

 

6,687 

 

 

 —

 

 

 —

 

 

6,690 

Stock-based compensation expense

 

 —

 

 

 —

 

 

4,381 

 

 

 —

 

 

 —

 

 

4,381 

Balance at March 31, 2019

 

152,672 

 

$

153 

 

$

1,107,121 

 

$

 

$

(1,012,430)

 

$

94,850 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2017

 

116,277 

 

$

116 

 

$

965,752 

 

$

(32)

 

$

(879,733)

 

$

86,103 

Net loss

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

(24,179)

 

 

(24,179)

Other comprehensive loss

 

 —

 

 

 —

 

 

 —

 

 

(6)

 

 

 —

 

 

(6)

ASC 606 adoption effect

 

 

 

 

 

 

 

 

 

 

 

 

 

189 

 

 

189 

Issuance of common stock in conjunction with equity plans

 

1,220 

 

 

 

 

2,485 

 

 

 —

 

 

 —

 

 

2,487 

Issuance of common stock from ATM equity offering, net of issuance costs

 

14,375 

 

 

14 

 

 

32,848 

 

 

 —

 

 

 —

 

 

32,862 

Stock-based compensation expense

 

 —

 

 

 —

 

 

5,282 

 

 

 —

 

 

 —

 

 

5,282 

Balance at March 31, 2018

 

131,872 

 

$

132 

 

$

1,006,367 

 

$

(38)

 

$

(903,723)

 

$

102,738 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 







See accompanying notes to the consolidated financial statements.

6

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)





 

 

 

 

 



 

 

 

 

 



Three Months Ended March 31,

(in thousands)

2019

 

2018

Cash flows from operating activities

 

 

 

 

 

Net loss

$

(30,324)

 

$

(24,179)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

Depreciation

 

1,796 

 

 

1,802 

Amortization of operating lease right-of-use assets

 

653 

 

 

 —

Amortization of debt discount and financing costs

 

279 

 

 

237 

Gain on derivative

 

(16)

 

 

(171)

Stock-based compensation

 

4,381 

 

 

5,282 

Amortization (accretion) from investment premium (discount)

 

(416)

 

 

(38)

Changes in assets and liabilities

 

 

 

 

 

Accounts receivable

 

1,316 

 

 

4,981 

Inventory

 

(1,888)

 

 

(2,720)

Prepaid expenses and other assets

 

87 

 

 

312 

Accounts payable

 

2,075 

 

 

(942)

Accrued expenses

 

(1,703)

 

 

(2,402)

Deferred service revenue

 

(230)

 

 

(307)

Other liabilities

 

(1,323)

 

 

(628)

Net cash used in operating activities

 

(25,313)

 

 

(18,773)

Cash flows from investing activities

 

 

 

 

 

Purchase of property and equipment

 

(1,253)

 

 

(344)

Purchase of investments

 

(17,623)

 

 

(31,547)

Sales of investments

 

 —

 

 

2,442 

Maturities of investments

 

56,860 

 

 

21,700 

Net cash provided by (used in)  investing activities

 

37,984 

 

 

(7,749)

Cash flows from financing activities

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

6,690 

 

 

2,487 

Proceeds from issuance of common stock from underwritten public equity offering, net of issuance costs

 

 —

 

 

32,986 

Net cash provided by financing activities

 

6,690 

 

 

35,473 

Net increase in cash and cash equivalents and restricted cash

 

19,361 

 

 

8,951 

Cash and cash equivalents and restricted cash at beginning of period

 

23,344 

 

 

21,007 

Cash and cash equivalents and restricted cash at end of period

$

42,705 

 

$

29,958 

Cash and cash equivalents at end of period

 

38,205 

 

 

25,458 

Restricted cash at end of period

 

4,500 

 

 

4,500 

Cash and cash equivalents and restricted cash at end of period

$

42,705 

 

$

29,958 



 

 

 

 

 

See accompanying notes to the condensed consolidated financial statements.







 

7

 


 

Table of Contents

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1. OVERVIEW

We design, develop and manufacture sequencing systems to help scientists resolve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT®) sequencing technology, our products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Our technology provides high accuracy, ultra-long reads, uniform coverage and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing.  

On November 1, 2018, we entered into an Agreement and Plan of Merger with Illumina, Inc. (“Illumina”) and FC Ops Corp., a wholly-owned subsidiary of Illumina (the “Merger Agreement”) pursuant to which Illumina will acquire us  for $8.00 per share of our common stock in an all-cash transaction and FC Ops Corp. will be merged with and into us (the “Merger”), with us surviving the Merger and becoming a wholly-owned subsidiary of Illumina. Completion of the transaction is subject to terms and conditions set forth in the Merger Agreement, including expiration or termination of any waiting periods applicable to the consummation of the Merger under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and clearance under the antitrust laws of certain non-U. S. jurisdictions. At a Special Meeting of Stockholders held on January 24, 2019, our stockholders, among other things, approved the adoption of the Merger Agreement. The Merger has been notified to the United States Federal Trade Commission (“FTC”) and to the Competition and Markets Authority of the United Kingdom (“CMA”). We and Illumina continue to expect the Merger to be completed in mid-2019, at which time we will become a wholly-owned subsidiary of Illumina and will cease to be a publicly-traded company. No assurance can be given that the required regulatory approvals will be obtained or that the required conditions to closing will be satisfied, and, even if all such approvals are obtained and the conditions are satisfied, no assurance can be given as to the terms, conditions and timing of the approvals. Under certain circumstances specified in the Merger Agreement, Illumina may be required to pay us a termination fee of $98.0 million (the “Reverse Termination Fee”).  For more information about the effects of our agreement to be acquired by Illumina please see Risk Factors under the section “Risks Related to Our Business”.

The names “Pacific Biosciences,” “PacBio,” “SMRT,” “SMRTbell,” “Sequel” and our logo are our trademarks.



NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

In the opinion of management, our accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) have been prepared on a consistent basis with our December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods.

The consolidated financial statements include the accounts of Pacific Biosciences and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Our estimates include, but are not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the valuation of a financing derivative and long-term notes, the valuation and recognition of share-based compensation, the expected renewal period for service contracts, the useful lives assigned to long-lived assets, the computation of provisions for income taxes and the determination of the internal borrow rate used in calculating the operating lease right-of-use assets and operating lease liabilities. Actual results could differ materially from these estimates.

8

 


 

Table of Contents

 

Fair Value of Financial Instruments

The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.

The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:

·

Level 1: quoted prices in active markets for identical assets or liabilities;

·

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

·

Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

  

We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.

We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of March 31, 2019 and December 31, 2018 respectively (in thousands):









 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



March 31, 2019

 

December 31, 2018

(in thousands)

Level 1

 

Level 2

 

Level 3

 

Total

 

Level 1

 

Level 2

 

Level 3

 

Total

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

$

29,329 

 

$

 —

 

$

 —

 

$

29,329 

 

$

18,844 

 

$

 —

 

$

 —

 

$

18,844 

Commercial paper

 

 —

 

 

8,876 

 

 

 —

 

 

8,876 

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Total cash and cash equivalents

 

29,329 

 

 

8,876 

 

 

 —

 

 

38,205 

 

 

18,844 

 

 

 —

 

 

 —

 

 

18,844 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

 —

 

 

31,306 

 

 

 —

 

 

31,306 

 

 

 —

 

 

53,469 

 

 

 —

 

 

53,469 

Corporate debt securities

 

 —

 

 

6,979 

 

 

 —

 

 

6,979 

 

 

 —

 

 

10,214 

 

 

 —

 

 

10,214 

US government & agency securities

 

 —

 

 

6,382 

 

 

 —

 

 

6,382 

 

 

 —

 

 

19,827 

 

 

 —

 

 

19,827 

Total investments

 

 —

 

 

44,667 

 

 

 —

 

 

44,667 

 

 

 —

 

 

83,510 

 

 

 —

 

 

83,510 

Long-term restricted cash:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

4,500 

 

 

 —

 

 

 —

 

 

4,500 

 

 

4,500 

 

 

 —

 

 

 —

 

 

4,500 

Total assets measured at fair value

$

33,829 

 

$

53,543 

 

$

 —

 

$

87,372 

 

$

23,344 

 

$

83,510 

 

$

 —

 

$

106,854 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financing derivative

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

16 

 

$

16 

Total liabilities measured at fair value

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

16 

 

$

16 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



9

 


 

Table of Contents

 

The estimated fair value of the Financing Derivative liability was determined using Level 3 inputs, or significant unobservable inputs.





During the three months ended March 31, 2019, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

We determined the fair value of the Notes from the debt facility that we entered into during the first quarter of 2013 using Level 3 inputs, or significant unobservable inputs. The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using 8.4% and 9.6% weighted average market yield at March 31, 2019 and December 31, 2018, respectively. Refer to Note 5. Notes Payable for additional details regarding the Notes. The estimated fair value and carrying value of the Notes are as follows (in thousands):

The estimated fair value and carrying value of the Notes are as follows (in thousands):















 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



March 31, 2019

 

December 31, 2018



Fair Value

 

Carrying Value

 

Fair Value

 

Carrying Value

Notes payable

$

16,083 

 

$

14,938 

 

$

15,915 

 

$

14,659 



Net Loss per Share

The following outstanding common stock options, restricted stock units, or “RSUs”, with time-based vesting and RSUs with performance-based vesting were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect. See Note 7. Stockholders’ Equity for detailed information on RSUs with time-based vesting and RSUs with performance-based vesting.











 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 



 

Three Months Ended March 31,

 

 

(in thousands)

 

2019

 

2018

 

 

 

 

Options to purchase common stock

 

23,833 

 

28,879 

 

 

 

 

RSUs with time-based vesting

 

1,102 

 

355 

 

 

 

 

RSUs with performance-based vesting

 

138 

 

652 

 

 

 

 



Concentration and Other Risks

For the three months  ended March 31, 2019 and 2018, one of our customers, Gene Company Limited, accounted for approximately 17% and 29% of our total revenue, respectively. Gene Company Limited is our distributor in China. 

Going Concern

Cash, cash equivalents and investments, excluding restricted cash, at March 31, 2019 totaled $82.9 million, compared to $102.4 million at December 31, 2018. We believe that our existing cash, cash equivalents and investments, together with the Reverse Termination Fee or other remedies we may receive if the Merger Agreement is terminated under certain circumstances, will be sufficient to fund our projected operating requirements for at least twelve months from the date of filing of this Quarterly Report on Form 10-Q. 

If the Merger Agreement is terminated and we are unable to obtain sufficient funds pursuant to the Merger Agreement, we may need to raise additional capital.  To the extent we raise additional funds through the sale of equity or convertible debt, the issuance of such securities will result in dilution to our stockholders. There can be no assurance that such funds will be available on favorable terms, or at all, particularly in light of restrictions under our debt agreement and the Merger Agreement. If adequate funds are not available, we may be required to obtain funds by entering into collaboration, licensing or debt agreements on unfavorable terms. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, or to increase or maintain the level of our research and development activities. If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of or eliminating some or all of our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products or cease operations. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements, and

10

 


 

Table of Contents

 

we are unable to raise capital, it would have a material adverse effect on our business, financial condition and results of operations.

Significant Accounting Policies

Except as noted below relating to our adoption of lease related accounting, there have been no material changes to our significant accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2018.



Recent Accounting Pronouncements

Recently Issued Accounting Standards



ASU 2016-13



In June 2016, the Financial Accounting Standards Board, or FASB,  issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. We plan to adopt ASU 2016-13 on January 1, 2020. However, we are still in the process of assessing the impact of the new standard on our results of operations or financial position.

Recently Adopted Accounting Standards



Adoption of ASU 2018-07

In June 2018, the FASB issued Accounting Standards Update, or ASU, 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, to simplify the accounting for nonemployee share-based payment transactions by expanding the scope of Accounting Standards Codification, or ASC, Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. Under the new standard, most of the guidance on stock compensation payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. This standard is effective for annual reporting periods beginning after December 15, 2018, including interim reporting periods within those annual reporting periods, with early adoption permitted. We adopted this standard beginning in January 1, 2019 and the adoption of this standard did not have a material impact on our condensed consolidated financial statements for the three months ended March 31, 2019.



Adoption of ASU 2018-02

In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that allows for an entity to elect to reclassify the income tax effects on items within accumulated other comprehensive income resulting from U.S. tax reform to retained earnings. The guidance is effective for fiscal years beginning after December 15, 2018 with early adoption permitted, including interim periods within those years. We adopted this standard beginning in January 1, 2019 and the adoption of this standard did not have a material impact on our condensed consolidated financial statements for the three months ended March 31, 2019.



Adoption of ASC 842

On January 1, 2019, we adopted the FASB Accounting Standards Codification, or ASC, Topic 842, Leases, or ASC 842, which requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the condensed consolidated balance sheet. As permitted by ASC 842, we elected the adoption date of January 1, 2019, which is the date of initial application. As a result, the condensed consolidated balance sheet prior to January 1, 2019 was not restated, continues to be reported under ASC Topic 840, Leases, or ASC 840, which did not require the recognition of operating lease liabilities on the condensed consolidated balance sheet, and is not comparative. The expense recognition for operating leases under ASC 842 is substantially consistent with ASC 840. As a result, there is no significant difference in our results of operations presented in our condensed consolidated statements of operations and comprehensive loss for each period presented.

11

 


 

Table of Contents

 

We adopted ASC 842 using a modified retrospective approach for leases existing at January 1, 2019. The adoption of ASC 842 had a substantial impact on our balance sheet. The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases.  Accordingly, adoption of this standard resulted in the recognition of operating lease right-of-use assets of $35.5 million and operating lease liabilities of $49.2 million comprised of $3.4 million of current operating lease liabilities and $45.8 million of non-current operating lease liabilities  on the condensed consolidated balance sheet as of January 1, 2019.

As permitted under ASC 842, we elected several practical expedients that permit us:

·

to not reassess whether a contract is or contains a lease; 

·

to not reassess the lease classification; 

·

to not reassess the initial direct costs as of the adoption date;

·

to not recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less; and

·

to not separate non-lease components for real estate leases.

The application of the practical expedients did not have a significant impact on the measurement of the operating lease liabilities. 

Service and other revenue can include some revenue from instrument lease agreements. Instrument leases are generally classified as operating-type leases and revenue from these leases is recognized on a straight-line basis over the respective lease term. Lease income was not material in fiscal 2018 or the first quarter of 2019.

Disclosure related to the amount, timing and uncertainty of cash flows arising from operating leases are included in “Leases” section of Note 6. Commitments and Contingencies.



12

 


 

Table of Contents

 

NOTE 3. CASH, CASH EQUIVALENTS AND INVESTMENTS

The following tables summarize our cash, cash equivalents and investments as of March 31, 2019 and December 31, 2018 (in thousands):







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



As of March 31, 2019 



 

 

Gross

 

Gross

 

 



Amortized

 

unrealized

 

unrealized

 

Fair



Cost

 

gains

 

losses

 

Value

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

$

29,329 

 

$

 —

 

$

 —

 

$

29,329 

Commercial paper

 

8,877 

 

 

 —

 

 

(1)

 

 

8,876 

Total cash and cash equivalents

 

38,206 

 

 

 —

 

 

(1)

 

 

38,205 

Investments:

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

31,309 

 

 

 

 

(4)

 

 

31,306 

Corporate debt securities

 

6,970 

 

 

10 

 

 

(1)

 

 

6,979 

US government & agency securities

 

6,381 

 

 

 

 

 —

 

 

6,382 

Total investments

 

44,660 

 

 

12 

 

 

(5)

 

 

44,667 

Total cash, cash equivalents and investments

$

82,866 

 

$

12 

 

$

(6)

 

$

82,872 

Long-term restricted cash:

 

 

 

 

 

 

 

 

 

 

 

Cash

$

4,500 

 

$

 —

 

$

 —

 

$

4,500 



 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



As of December 31, 2018 



 

 

Gross

 

Gross

 

 



Amortized

 

unrealized

 

unrealized

 

Fair



Cost

 

gains

 

losses

 

Value

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

$

18,844 

 

$

 —

 

$

 —

 

$

18,844 

Commercial paper

 

 —

 

 

 —

 

 

 —

 

 

 —

Total cash and cash equivalents

 

18,844 

 

 

 —

 

 

 —

 

 

18,844 

Investments:

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

53,493 

 

 

 —

 

 

(24)

 

 

53,469 

Corporate debt securities

 

10,223 

 

 

 

 

(12)

 

 

10,214 

US government & agency securities

 

19,830 

 

 

 —

 

 

(3)

 

 

19,827 

Total investments

 

83,546 

 

 

 

 

(39)

 

 

83,510 

Total cash, cash equivalents and investments

$

102,390 

 

$

 

$

(39)

 

$

102,354 

Long-term restricted cash:

 

 

 

 

 

 

 

 

 

 

 

Cash

$

4,500 

 

$

 —

 

$

 —

 

$

4,500 



 

 

 

 

 

 

 

 

 

 

 



The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March 31, 2019:





 

 



 

 

(in thousands)

Fair Value

Due in one year or less

$

53,543 

Total investments

$

53,543 



Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.



13

 


 

Table of Contents

 

NOTE 4. BALANCE SHEET COMPONENTS



Inventory



As of March 31, 2019 and December 31, 2018, our inventory consisted of the following components:







 

 

 

 

 



 

 

 

 

 



March 31,

 

December 31,

(in thousands)

2019

 

2018

Purchased materials

$

6,253 

 

$

6,222 

Work in process

 

9,104 

 

 

7,341 

Finished goods

 

4,293 

 

 

4,315 

Inventory

$

19,650 

 

$

17,878 

  







NOTE 5. NOTES PAYABLE

Facility Agreement

Under the terms of our February 2013 debt agreement with Deerfield (the “Facility Agreement”), we received $20.5 million and issued promissory notes in the aggregate principal amount of $20.5 million (the “Notes”). The Notes bear simple interest at a rate of 8.75% per annum, payable quarterly in arrears commencing on April 1, 2013 and on the first business day of each January, April, July and October thereafter. The Facility Agreement has a maximum term of seven years. We received net proceeds of $20.0 million, representing $20.5 million of gross proceeds, less a $500,000 facility fee, before deducting other expenses of the transaction. On June 23, 2017, pursuant to a partial exercise by the Notes holders of their right to elect to receive up to 25% of the net proceeds from any financing that includes an equity component, we paid $4.5 million of outstanding principal, together with accrued and unpaid interest, to one of the Note holders with proceeds from our underwritten public equity offering. As of March 31, 2019, a balance of $16.0 million aggregate principal amount of debt remained outstanding under this facility and due in February 2020, and we reclassified the notes payable from “Notes payable, non-current” to “Notes payable, current”.

The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on our ability to incur additional indebtedness or liens on our assets, except as permitted under the Facility Agreement. In addition, the Facility Agreement requires us to maintain consolidated cash and cash equivalents on the last day of each calendar quarter of not less than $2.0 million. As security for our repayment of our obligations under the Facility Agreement, we granted the lenders a security interest in substantially all of our property and interests in property.

Subject to certain exceptions set forth in the Facility Agreement, holders representing a majority of the aggregate principal amount of the outstanding Notes issued pursuant to the Facility Agreement may elect to receive up to 25% of the net proceeds from any financing that includes an equity component. To the extent we raise additional capital in the future through the sale of common stock, including without limitation, sales of common stock pursuant to an “at-the-market” offering program, we may be obligated, at the election of the holders of the Notes, to pay 25% of the net proceeds from any such financing activities as partial payment of the Notes.

14

 


 

Table of Contents

 

Financing Derivative

A number of features embedded in the Notes required accounting for as a derivative, including the indemnification of certain withholding taxes and the acceleration of debt upon (i) a qualified financing, (ii) an event of default, (iii) a major transaction, and (iv) the exercise of the warrant via offset to debt principal. These features represent a single derivative (the “Financing Derivative”) that was bifurcated from the debt instrument and accounted for as a liability at fair value, with changes in fair value between reporting periods recorded in other income (expense), net.

The estimated fair value of the Financing Derivative was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 8.4% and 9.6% weighted average market yield at March 31, 2019 and December 31, 2018, respectively. The estimated fair value of the Financing Derivative as of March 31, 2019 and December 31, 2018 was $0 and $16,000, respectively.

As of March 31, 2019, payments due under our notes payable, which include interest and principal, were as follows:







 

 



Amount



(in thousands)

Remainder of 2019

$

1,047 

2020

 

16,491 

Total remaining payments

 

17,538 

Less: interest and discounts

 

(2,600)

Notes payable

$

14,938 











NOTE 6. COMMITMENTS AND CONTINGENCIES

Leases

As of January 1, 2019, we lease approximately 180,000 square feet in 1305 O’Brien Drive, Menlo Park, California, where we house our headquarters, research and development, service and support functions, and our in-house manufacturing operations for which the right of use assets totaled $35.3 million. We also lease a sales office facility in Singapore and engineering support facilities in Allen, Texas for which the right of use assets totaled $0.2 million as of January 1, 2019.

All our leases are operating leases. Operating lease assets and liabilities are reflected within “Operating lease right-of-use assets, net”, “Operating lease liabilities, current” and “Operating lease liabilities, non-current” on the condensed consolidated balance sheets. These assets and liabilities are recognized at the commencement date based on the present value of remaining minimum lease payments over the lease term using our estimated secured incremental borrowing rates at the effective date of January 1, 2019. Lease payments included in the measurement of the lease liability comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.

We often have options to renew lease terms for buildings. For our 1305 O’Brien lease, the renewal option is 5 years and the rent will be based on fair market value at the time of renewal and was not included in the lease term. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The weighted average remaining lease term for our operating leases as of March 31, 2019 was 8.6 years.

The discount rate implicit within our leases is generally not determinable and therefore we determine the discount rate based on our incremental borrowing rate. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. The weighted average discount rate used to measure our operating lease liabilities as of March 31, 2019 was 7.9%.

15

 


 

Table of Contents

 

The following table presents information at the amount, timing and uncertainty of cash flows arising from our operating leases as of March 31, 2019:











 

 

Maturity of Lease Liabilities

Amount

Years ending December 31,

(in thousands)

Remaining of 2019

$

5,262 

2020

 

7,136 

2021

 

7,305 

2022

 

7,488 

2023

 

7,704 

Thereafter

 

31,518 

Total undiscounted operating lease payments

 

66,413 

Less: imputed interest

 

(18,031)

Present value of operating lease liabilities

 

48,382 



 

 

Balance Sheet Classification

 

 

Operating lease liabilities, current

 

3,521 

Operating lease liabilities, non-current

 

44,861 

Total operating lease liabilities

 

48,382 







Cash Flows

An initial right-of-use asset of $35.5 million was recognized as a non-cash asset addition on the condensed consolidated balance sheet as of January 1, 2019 with the adoption of the new lease accounting standard.  Cash paid for amounts included in the present value of operating lease liabilities was $1.8 million during the first quarter of 2019 and included in operating cash flow.



Operating Lease Costs

Operating lease costs were $1.6 million during the first quarter of 2019,  primarily related to our operating leases, but also include immaterial amounts for variable leases.

For our 1305 O’Brien lease, we were required to establish a letter of credit for the benefits of the landlord and to submit $4.5 million as a deposit for the letter of credit in October 2015; and, as such, $4.5 million was recorded at such time and continued to be recorded in “Long-term restricted cash” in the condensed consolidated balance sheet as of both March 31, 2019 and December 31, 2018. Pursuant to the terms of the 1305 O’Brien lease, the $4.5 million in restricted cash was reduced to $4.0 million as of May 1, 2019 and will reduce again over time.

Contingencies

We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

Legal  

Legal Proceedings Regarding the Merger

In connection with the proposed acquisition of us by Illumina, five lawsuits were filed, with each lawsuit naming us and our directors as defendants. Three putative class action complaints, captioned Wang v. Pacific Biosciences of California, Inc., et al., No. 3:18-cv-7450 (N.D. Cal.), Morrison v. Pacific Biosciences of California, Inc., et al., No. 3:18-cv-7654 (N.D. Cal.), and Speiser v. Pacific Biosciences of California, Inc., et al., No. 3:19-cv-0072 (N.D. Cal.), were filed in the United States District Court for the Northern District of California on December 11, 2018, December 20, 2018, and January 4, 2019, respectively. A fourth putative class action complaint, captioned Rosenblatt v. Pacific Biosciences of California, Inc., et al., No. 1:18-cv-2005 (D. Del.), was filed in the United States District Court for the District of Delaware on December 18, 2018. An individual complaint, captioned Washington v. Pacific Biosciences of California, Inc., et al., No. 5:18-cv-7614 (N.D. Cal.), was filed in the United States District Court for the Northern District of California on December

16

 


 

Table of Contents

 

19, 2018. Each of these lawsuits asserted claims under Section 14(a) and Section 20(a) of the Securities Exchange Act of 1934 in connection with the disclosures contained in our preliminary proxy statement on Schedule 14A, filed with the Securities Exchange Commission (the “SEC”) on December 5, 2018, our definitive proxy statement on Schedule 14A, filed with the SEC on December 18, 2018, or both. The complaints sought a variety of equitable and injunctive relief including, among other things, enjoining the consummation of the acquisition and awarding the plaintiffs costs and attorneys’ fees.

Although our management believed that the claims were without merit, we agreed to make supplemental disclosures in exchange for plaintiffs’ agreement that the supplemental disclosures would moot their claims. We made these supplemental disclosures in a proxy statement amendment on Schedule 14A, filed with the SEC on January 18, 2019.

On January 29, 2019, all parties to each of the lawsuits reached an agreement pursuant to which we would pay a total of $300,000 in attorneys’ fees to the plaintiffs. On January 29, 2019, each plaintiff filed a voluntary dismissal of his or her lawsuit. As of March 31, 2019, we accrued a total amount of $300,000 for the five lawsuits filed in 2018 and the first quarter of 2019.  

USITC Proceedings

On November 2, 2016, we filed a complaint against Oxford Nanopore Technologies Ltd. (“ONT Ltd.”), Oxford Nanopore Technologies, Inc. (“ONT Inc.”) and Metrichor, Ltd. (“Metrichor” and, together with ONT Ltd. and ONT Inc., “ONT”) with the U.S. International Trade Commission (“USITC”) for patent infringement. On December 5, 2016, the USITC provided notice that an investigation had been instituted based on the complaint. We sought exclusionary relief with respect to several ONT products, including ONT’s MinION and PromethION devices. The complaint was based on our U.S. Patent No. 9,404,146, entitled “Compositions and methods for nucleic acid sequencing” which covers novel methods for sequencing single nucleic acid molecules using linked double-stranded nucleic acid templates, providing improved sequencing accuracy. On March 1, 2017, we filed an amended complaint to add a second patent in the same patent family, U.S. Patent No. 9,542,527, which was granted on January 10, 2017, to the investigation. We sought, among other things, an exclusion order permanently barring entry of infringing ONT products into the United States, and a cease and desist order preventing ONT from advertising and selling infringing products in the United States. On May 23, 2017, the Administrative Law Judge (“ALJ”) assigned to the matter issued an order construing certain claim terms of the asserted patents. On June 8, 2017, ONT filed a summary determination motion to terminate the proceedings based on the ALJ’s claim construction decision, and we did not oppose the motion. The ALJ granted the motion on July 19, 2017, and, on July 31, 2017, we filed a petition to review with the USITC to correct what we believe was an incorrect construction of the claims. On September 5, 2017, the USITC issued a notice granting our petition to review the ALJ’s claim construction decision. On February 7, 2018, the USITC issued a notice indicating that it had determined to adopt the ALJ’s claim construction and terminating the investigation. On February 13, 2018, we filed a petition to appeal the USITC’s ruling to the U.S. Court of Appeals for the Federal Circuit. (“Federal Circuit”). An oral hearing for this appeal was held on February 8, 2019. On February 12, 2019, the Federal Circuit filed a judgement affirming the USITC claim construction under Federal Circuit Rule 36 without a written opinion.

U.S. District Court Proceedings

On March 15, 2017, we filed a complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-275 (“275 Action”)). The complaint is based on our U.S. Patent No. 9,546,400 (the “’400 Patent”), entitled “Nanopore sequencing using n-mers” which covers novel methods for nanopore sequencing of nucleic acid molecules using the signals from multiple monomeric units. This patent was granted on January 17, 2017. We are seeking remedies including injunctive relief, damages and costs. On May 8, 2017, the defendants filed a motion to dismiss the complaint, alleging that the asserted patent claims recite patent ineligible subject matter. On November 9, 2017, the judge denied ONT Inc.’s motion to dismiss. On June 1, 2018, we filed a motion for leave to amend the complaint to add ONT Ltd. as a defendant.  On August 20, 2018, the judge granted our motion, and on August 23, 2018, we filed an amended complaint, adding ONT Ltd. as a defendant in the 275 Action.  On September 24, 2018, ONT Ltd. filed a motion to dismiss the amended complaint, alleging failure to state a claim. On April 29, 2019, the judge denied ONT Ltd.’s motion to dismiss.

On September 12, 2018, ONT Inc. filed its answer, defenses and counterclaims in the 275 Action, seeking declaratory judgements of non-infringement and invalidity of the ’400 Patent and unenforceability of the ’400 Patent based on alleged inequitable conduct before the U.S. Patent and Trademark Office (“USPTO”), as well as antitrust, false advertising, and unfair competition counterclaims. On September 25, 2018, it was stipulated that the motion to dismiss ONT Inc.’s counterclaims that we submitted in the 1353 Action would also serve as our motion to dismiss ONT Inc.’s counterclaims in the 275 Action. On February 19, 2019, the judge granted our motion to dismiss ONT Inc.’s antitrust, false advertising, and unfair competition counterclaims in each action.

Related to the 275 Action, on March 15, 2018, ONT Inc. filed a petition to institute an inter partes review with the Patent Trial and Appeal Board (“PTAB”) of the USPTO, alleging invalidity of the ’400 Patent.  On July 5, 2018, we filed a preliminary response outlining for the PTAB why the petition should be denied and no review should be instituted. On

17

 


 

Table of Contents

 

September 25, 2018, the PTAB denied ONT Inc.’s petition for institution of the inter partes review for all claims of the ’400 Patent.

On September 25, 2017, we filed a second complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-1353 (“1353 Action”)). The complaint is based on our U.S. Patent No. 9,678,056 (the “’056 Patent”) entitled “Control of Enzyme Translation in Nanopore Sequencing”, granted June 13, 2017, and U.S. Patent No. 9,738,929 (the “’929 Patent”) entitled “Nucleic Acid Sequence Analysis”, granted August 22, 2017. We are seeking remedies including injunctive relief, damages and costs. On December 14, 2017, the defendants filed a motion to dismiss the complaint, alleging that the asserted patent claims in the ’929 Patent recite patent ineligible subject matter. On March 22, 2018, the judge denied ONT Inc.’s motion to dismiss. On March 28, 2018, we added a claim for infringement of our U.S. Patent No. 9,772,323 (the “’323 Patent”), entitled “Nanopore sequencing using n-mers.” On June 1, 2018, we filed a motion for leave to amend the complaint to add ONT Ltd. as a defendant. On August 20, 2018, the judge granted our motion, and on August 23, 2018 we filed an amended complaint, adding ONT Ltd. as a defendant in the 1353 Action.  On September 24, 2018, ONT filed a motion to dismiss the amended complaint, alleging failure to state a claim. On April 24, 2019, the judge denied ONT Ltd.’s motion to dismiss.

On April 25, 2018, ONT Inc. filed its answer, defenses and counterclaims in the 1353 Action, seeking declaratory judgements of non-infringement and invalidity of the ’056 and ’323 Patents and unenforceability of the ’056 and ’323 Patents based on alleged inequitable conduct before the USPTO, as well as antitrust, false advertising, and unfair competition counterclaims. On June 15, 2018, we filed a motion to dismiss ONT Inc.’s counterclaims in the 1353 Action and, on June 18, 2018, we filed a motion to bifurcate and stay discovery on ONT Inc.’s antitrust counterclaims in the 1353 Action. On February 19, 2019, the judge granted our motion to dismiss ONT Inc.’s antitrust, false advertising, and unfair competition counterclaims.

Related to the 1353 Action, on September 24, 2108, ONT Inc. filed a first petition to institute an inter partes review with the PTAB of the USPTO, alleging invalidity of the ’929 Patent.  On September 25, 2018, ONT Inc. filed a second petition to institute an inter partes review of the ’929 Patent based on the same art and arguments as the first petition.  ONT Inc. subsequently filed a motion to withdraw the first petition, which motion was granted. On January 11, 2019, we filed a preliminary response to the second petition outlining for the PTAB why the petition should be denied, and no review should be instituted. On March 26, 2019, the PTAB denied ONT Inc.’s petition for institution of the inter partes review for all claims of the ’929 Patent.    

Also related to the 1353 Action, on September 25, 2018, ONT Inc. filed a petition to institute an inter partes review with the PTAB of the USPTO, alleging invalidity of the ’056 Patent. On February 13, 2019, we filed a preliminary response to the second petition outlining for the PTAB why the petition should be denied and no review should be instituted. On March 25, 2019, ONT Inc. moved to withdraw its petition for institution of the inter partes review of the ’056 Patent, which motion was granted by the PTAB on March 26, 2019, thus terminating the proceedings.

A claim construction (or “Markman”) hearing for the U.S. District Court matters was held on December 17, 2018. On March 6, 2019, a claim construction order construing various claim terms in the patents in suit was issued. A trial for the U.S. District Court matters is scheduled to occur in March 2020.

UK and German Court Proceedings

On February 2, 2017, we filed a claim in the High Court of England and Wales against ONT Ltd. and Metrichor for infringement of Patent EP(UK) 3 045 542 (the “’542 Patent”), which is in the same patent family as the patents asserted in the USITC action referred to above.  We sought remedies including injunctive relief, damages, and costs. On March 27, 2017, the defendants in the case filed their defense and counterclaim, denying infringement and seeking a declaration that the asserted patent is invalid. We filed our reply and defense to counterclaim on April 12, 2017.  A case management conference was held on June 13, 2017.  On August 31, 2017 we added a claim for infringement of a newly granted divisional, EP(UK) 3 170 904 (the “’904 Patent”).   On December 22, 2017, ONT Ltd. added to the action a request for declaration of non-infringement of its 1D2 product. On January 12, 2018 we served reply to ONT Ltd.’s request for a declaration of non-infringement, asserting infringement of both patents by ONT’s 1D2 product. A trial for these matters was scheduled to occur in May 2018. 

On April 21, 2017, ONT Ltd. and Harvard University filed a claim against us in the High Court of England and Wales for infringement of Patent EP(UK) 1 192 453 (the “’453 Patent”), a patent owned by Harvard University and entitled “Molecular and atomic scale evaluation of biopolymers,” and for which ONT Ltd. alleges it holds an exclusive license.  ONT Ltd. and Harvard University sought remedies including injunctive relief, damages, and costs. On April 25, 2017, ONT Ltd. announced that it also had filed a claim against us in the District Court of Mannheim, Germany, for infringement of the German version of the patent.  On November 2, 2017, we filed our statement of defense in the German infringement matter and we also filed a separate nullity action in Germany to establish that the ’453 Patent is invalid.  On December 6, 2017, we filed a cross-complaint in the German infringement matter alleging ONT Ltd.’s infringement in Germany of our ’542 Patent.  The trial date for the German infringement matter and cross-complaint was set for July 27, 2018.  A trial for the UK matter

18

 


 

Table of Contents

 

was scheduled to occur in March 2019. 

On May 8, 2018, the parties entered a settlement of all UK and German court proceedings pending as of such date. Under the terms of the settlement, ONT agreed not to make, dispose of, use or import any “2D” nanopore sequencing products, or to induce or assist others to carry out a “2D” sequencing process, in the UK or Germany, through the end of 2023. During this time, we agreed not to assert the ’542 Patent and ’904 Patent against either ONT or its customers in the UK or Germany. Accordingly, the High Court of England and Wales entered an order staying our UK action against ONT through the end of 2023. As part of the settlement, ONT and Harvard University dismissed their UK and German actions under the ’453 Patent and agreed not to assert the ’453 Patent against us or our customers through the end of 2023. We correspondingly agreed to dismiss our separate German nullity action seeking to invalidate the ’453 Patent, which expires on June 22, 2020.

Related to these proceedings, on August 15, 2017, ONT Ltd. filed a notice of opposition to our ’542 Patent with the European Patent Office, and on August 16, 2017, an anonymous party filed a second notice of opposition to the same patent, each alleging invalidity of the patent.  On April 5, 2018, we filed our response to the combined opposition. On January 22, 2019, an oral hearing in the matter occurred and the European Patent Office rendered a decision in favor of the opponents. We believe the European Patent Office erred in its decision and we intend to appeal the decision. The ’542 Patent will remain in effect while the appeal is pending. Our settlement agreement with ONT Ltd. and Harvard University will also remain in effect regardless of the outcome of the appeal.

Also related to these proceedings, on May 16, 2018, ONT Ltd. filed a notice of opposition to our ’904 Patent with the European Patent Office alleging invalidity of the ’904 Patent. On October 11, 2018, we filed our response to the opposition. An oral hearing in the matter is scheduled for July 16, 2019.

Litigation is inherently unpredictable, and it is too early in the proceedings to predict the outcome of these lawsuits or any impact they may have on us. As such, the estimated financial effect associated with these complaints cannot be made as of the date of filing of this Annual Report on Form 10-K. Litigation is a significant ongoing expense with an uncertain outcome, and has been in the past and may in the future be a material expense for us. Management believes this investment is important to protect our intellectual property position, even recognizing the uncertainty of the outcome.

Other Proceedings

From time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.

Indemnification

Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded at March 31, 2019.



NOTE 7. STOCKHOLDERS’ EQUITY



Underwritten Public Equity Offering

19

 


 

Table of Contents

 

In August 2017, we filed a shelf registration statement on Form S-3 with the SEC pursuant to which we may, from time to time, sell up to an aggregate of $150.0 million of our common stock, preferred stock, depository shares, warrants, units or debt securities. On August 18, 2017, the registration statement was declared effective by the SEC, which allows us to access the capital markets for the three-year period following this effective date.

In February 2018, we entered into an underwriting agreement,  relating to the public offering of 12,500,000 shares of our common stock, $0.001 par value per share, at a price to the public of $2.40 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of our common stock, which was subsequently exercised in full, and the offering as well as the sale of shares of common stock subject to the underwriters’ option, closed in February 2018. In total, we sold 14.4 million shares of our common stock at a price of $2.40 per share. We paid a commission equal to 4% of the gross proceeds from the sale of shares of our common stock under the underwriting agreement. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $33.1 million, which excludes approximately $0.3 million of offering expenses. 

In September 2018, we entered into an underwriting agreement,  relating to the public offering of 14,117,647 shares of our common stock, $0.001 par value per share, at a price to the public of $4.25 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2,117,647 shares of our common stock, which was subsequently exercised in full, and the offering as well as the sale of shares of common stock subject to the underwriters’ option, closed in September 2018. In total, we sold 16.2 million shares of our common stock at a price of $4.25 per share. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock under the underwriting agreement. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $64.9 million, excluding approximately $0.2 million of offering expenses. 

In total, for the year ended December 31, 2018, we issued 30.6 million shares of our common stock through our two underwritten public offerings with a weighted average offering price of $3.38 per share. The total net proceeds to us from the two offerings, after deducting the underwriting commissions and offering expenses, were approximately $97.5 million.

Subject to certain exceptions set forth in our Facility Agreement, holders of our Notes may elect to receive up to 25% of the net proceeds from financing activities that include an equity component as prepayment of the Notes to be applied first, to accrued and unpaid interest and second, to principal. However, in both February 2018 and September 2018, holders representing a majority of the aggregate principal amount of the outstanding Notes waived such right in connection with the issuance and sale of shares of common stock in our public offering.



Equity Plans

As of March 31, 2019, we had three active equity compensation plans: the 2010 Equity Incentive Plan (“2010 Plan”), the 2010 Outside Director Equity Incentive Plan (“2010 Director Plan”), and the 2010 Employee Stock Purchase Plan (“ESPP”). Under the 2010 Plan, with the approval of the Compensation Committee of the Board of Directors, we may grant restricted stock, RSU, stock appreciation rights and new shares of common stock upon exercise of stock options.

In January 2019, an additional 7.5  million shares were reserved under the 2010 Plan, and an additional 3.0 million shares were reserved under the ESPP pursuant to the evergreen provisions thereof.

20

 


 

Table of Contents

 

Stock Options

The following table summarizes stock option activity for all our stock option plans for the three months  ended March 31, 2019 (in thousands, except per share amounts):





 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

 

Stock Options Outstanding



 

 

 

 

 

 

 

Weighted



Shares available

 

Number

 

 

 

 

average



for grant

 

of shares

 

Exercise price

 

exercise price

Balances, December 31, 2018

12,279 

 

25,176 

 

$

 1.1616.00 

 

$

5.66 

Additional shares reserved 

7,512 

 

 

 

 

 

 

 

 

Options granted

 —

 

 —

 

 

 —

 

 

 —

Options exercised

—  

 

(801)

 

 

1.167.05

 

 

4.84 

Options canceled

542 

 

(542)

 

 

2.5416.0 

 

10.27 

Balances, March 31, 2019

20,333 

 

23,833 

 

$

 1.1616.00 

 

$

5.58 



Restricted Stock Units, or “RSUs”

Time-based RSUs 

Beginning in the three months  ended March 31, 2018, the Compensation Committee of the Board of Directors has approved awards of RSUs with time-based vesting from the 2010 Plan to certain employees. Each RSU represents one equivalent share of our common stock to be awarded after the vesting period. These RSUs vest over four years at a rate of 25% annually. The fair value for these RSUs is based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. The number of RSUs vested includes shares of common stock that we will withhold on behalf of employees to satisfy the minimum statutory tax withholding requirements. RSUs that are expected to vest are net of estimated future forfeitures.

The following table summarizes the time-based RSUs activity for the three months  ended March 31, 2019 (in thousands, except per share amounts):







 

 

 

 



 

 

Weighted average



Number

 

grant date



of shares

 

fair value

RSUs outstanding at December 31, 2018

371 

 

$

3.20 

RSUs granted

815 

 

 

7.18 

RSUs released

(78)

 

 

2.58 

RSUs forfeited

(6)